Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pioglitazone 15 mg or 30 mg as add-on therapy to metformin and dapagliflozin in inadequately controlled type 2 diabetes; study complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Pioglitazone 15 mg or 30 mg (pioglitazone)

Snippet

Sponsor: Boryung Pharmaceutical Co., Ltd | Conditions: Type2 Diabetes | Phase 3 | Status: COMPLETED